The primary objective of this study is to evaluate the efficacy of BIO-K+ CL1285 for prevention of recurrent Clostridium difficile infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
140
2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
2 capsules of placebo (no live cells), consumed once daily for 60 days
Parker Jewish Institute
New Hyde Park, New York, United States
Incidence of recurrent Clostridium difficile infection
Time frame: 60 days
Duration of recurrent diarrhea episodes
Time frame: 60 days
Presence of gastrointestinal symptoms
Time frame: 60 days
Adverse events
Time frame: 60 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.